Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Acta Oncol. 2013 Feb;52(2):259-69. doi: 10.3109/0284186X.2012.744469. Epub 2012 Dec 7.
The Danish Breast Cancer Cooperative Group (DBCG) introduced BCT as a standard treatment in Denmark in 1990. The aim of this study was to investigate late morbidity, cosmetic outcome, and body image after BCT and to associate these outcome variables with patient, tumor, and treatment characteristics.
A total of 214 patients treated with BCT from 1989-2002 participated in a long-term follow-up visit comprising an interview, clinical examination, photos of the breast region and completion of a questionnaire on Body Image.
Median follow-up time was 12 years (range 7-20). Moderate to severe fibrosis was found in 23% of patients and was associated with chemotherapy [OR 2.6, CI (1.1; 5.9), p = 0.02], large breast size [OR 3.2, CI (1.6; 6.4), p = 0.001], and smoking [OR 2.4, CI (1.1; 4.9), p = 0.02]. Patients with a satisfactory cosmetic outcome, when assessed by a clinician, were characterized by small tumors [OR 3.2, CI (1.5; 6.8), p = 0.003] and small to medium sized breasts [OR 2.0, CI (1.1; 3.5), p = 0.002]. Fifty percent of patients scored good or excellent when assessed by a clinician compared to 88% when reported by the patients themselves. Patients satisfied with their own cosmetic outcome were the younger patients [< 50 years; OR 3.2, CI (1.1; 8.6), p = 0.03] with no postoperative complications [OR 3.3, CI (1.2; 9.2), p = 0.02]. Regarding body image 15% felt less feminine, 25% felt less sexually attractive, and 28% of patients had changed their clothing habits as a result of the disease or treatment.
The majority of patients were satisfied with their cosmetic outcome after BCT, whereas only half of the patients were found to have a good or excellent cosmetic outcome when assessed by the clinician. Body image was found to be only minimally disturbed in the majority of patients. The level of moderate to severe fibrosis was acceptable compared to both national and international studies with similar patient compositions.
丹麦乳腺癌合作组(DBCG)于 1990 年在丹麦将保乳疗法作为标准治疗引入。本研究旨在调查保乳治疗后的迟发性发病情况、美容效果和身体形象,并将这些结果变量与患者、肿瘤和治疗特征相关联。
1989-2002 年间接受保乳治疗的 214 例患者参加了一项长期随访,包括访谈、临床检查、乳房区域的照片和完成身体形象问卷。
中位随访时间为 12 年(7-20 年)。23%的患者存在中度至重度纤维化,与化疗相关[OR 2.6,CI(1.1;5.9),p=0.02],乳房较大[OR 3.2,CI(1.6;6.4),p=0.001],以及吸烟[OR 2.4,CI(1.1;4.9),p=0.02]。临床医生评估美容效果满意的患者,其肿瘤较小[OR 3.2,CI(1.5;6.8),p=0.003],乳房较小至中等大小[OR 2.0,CI(1.1;3.5),p=0.002]。与患者自己报告相比,临床医生评估有 50%的患者得分良好或优秀,而患者自己报告有 88%。对自己的美容效果满意的患者是年轻的患者[<50 岁;OR 3.2,CI(1.1;8.6),p=0.03],且无术后并发症[OR 3.3,CI(1.2;9.2),p=0.02]。关于身体形象,15%的患者感觉不那么女性化,25%的患者感觉不那么性感,28%的患者因疾病或治疗而改变了他们的穿着习惯。
大多数患者对保乳治疗后的美容效果满意,但只有一半的患者经临床医生评估认为美容效果良好或优秀。大多数患者的身体形象仅受到轻微干扰。与具有相似患者组成的国内外研究相比,中度至重度纤维化的程度是可以接受的。